Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 9/20 | 0.50 |
| ▸ | BCHE | P06276 | 8/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 4/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5680377 | 1.00 | PPARG (0.57) | PPARGPTGS1PTGS2CYP1A2CYP3A4 | |
| SCHEMBL5680250 | 0.86 | PTGS1 (0.54) | PPARGPTGS1PTGS2CYP1A2CYP3A4 | |
| SCHEMBL2058864 | 0.81 | PTGS1 (0.60) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL25276111 | 0.80 | PTGS1 (0.57) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL30463837 | 0.80 | PTGS1 (0.57) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL18736234 | 0.80 | PTGS1 (0.57) | PPARGPTGS1PTGS2CYP1A2CYP3A4 | |
| SCHEMBL9690289 | 0.78 | ACHE (0.63) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL17289294 | 0.78 | PTGS1 (0.57) | PPARGPTGS1PTGS2CYP1A2CYP3A4 | |
| SCHEMBL30463821 | 0.78 | PTGS1 (0.66) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL9253766 | 0.78 | PTGS1 (0.66) | PTGS1PTGS2CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1233962-B1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE AS MEDICINES | SOD CONSEILS RECH APPLIC (FR) | 2006-03-01 | — | — | EP | claimed |
| US-20040180936-A1 | Heterocyclic compounds and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIEQUES (S.C.R.A.S.) | 2004-09-16 | — | — | US | claimed |
| EP-1233962-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE AS MEDICINES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-08-28 | — | — | EP | claimed |
| WO-2001032654-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE AS MEDICINES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2001-05-10 | — | — | WO | claimed |
| EP-1661564-A1 | Heterocyclic compounds and their pharmaceutical use | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2006-05-31 | — | — | EP | disclosed |
| EP-1233962-B1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE AS MEDICINES | SOD CONSEILS RECH APPLIC (FR) | 2006-03-01 | — | — | EP | disclosed |
| US-20040180936-A1 | Heterocyclic compounds and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIEQUES (S.C.R.A.S.) | 2004-09-16 | — | — | US | disclosed |
| US-6747024-B1 | INHIBITING CALPAIN AND/OR REACTIVE OXYGEN SPECIES IN WARM-BLOODED ANIMALS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-06-08 | — | — | US | disclosed |
| EP-1233962-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE AS MEDICINES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001032654-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE AS MEDICINES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180936-A1 | Heterocyclic compounds and their use as medicaments | CAPN1, CAPN2, CAPNS1 | PPARG 2430/4885PTGS1 47/4885PTGS2 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.